1
|
A Qualitative Risk Assessment for Bluetongue Disease and African Horse Sickness: The Risk of Entry and Exposure at a UK Zoo. Viruses 2022; 14:v14030502. [PMID: 35336912 PMCID: PMC8950286 DOI: 10.3390/v14030502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 02/25/2022] [Accepted: 02/25/2022] [Indexed: 12/10/2022] Open
Abstract
Bluetongue virus (BTV) and African horse sickness virus (AHSV) cause economically important diseases that are currently exotic to the United Kingdom (UK), but have significant potential for introduction and onward transmission. Given the susceptibility of animals kept in zoo collections to vector-borne diseases, a qualitative risk assessment for the introduction of BTV and AHSV to ZSL London Zoo was performed. Risk pathways for each virus were identified and assessed using published literature, animal import data and outputs from epidemiological models. Direct imports of infected animals, as well as wind-borne infected Culicoides, were considered as routes of incursion. The proximity of ongoing disease events in mainland Europe and proven capability of transmission to the UK places ZSL London Zoo at higher risk of BTV release and exposure (estimated as low to medium) than AHSV (estimated as very low to low). The recent long-range expansion of AHSV into Thailand from southern Africa highlights the need for vector competence studies of Palearctic Culicoides for AHSV to assess the risk of transmission in this region.
Collapse
|
2
|
Kopanke J, Lee J, Stenglein M, Carpenter M, Cohnstaedt LW, Wilson WC, Mayo C. Exposure of Culicoides sonorensis to Enzootic Strains of Bluetongue Virus Demonstrates Temperature- and Virus-Specific Effects on Virogenesis. Viruses 2021; 13:v13061016. [PMID: 34071483 PMCID: PMC8228769 DOI: 10.3390/v13061016] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/18/2021] [Accepted: 05/22/2021] [Indexed: 01/25/2023] Open
Abstract
Bluetongue virus (BTV) is a segmented RNA virus transmitted by Culicoides midges. Climatic factors, animal movement, vector species, and viral mutation and reassortment may all play a role in the occurrence of BTV outbreaks among susceptible ruminants. We used two enzootic strains of BTV (BTV-2 and BTV-10) to explore the potential for Culicoides sonorensis, a key North American vector, to be infected with these viruses, and identify the impact of temperature variations on virogenesis during infection. While BTV-10 replicated readily in C. sonorensis following an infectious blood meal, BTV-2 was less likely to result in productive infection at biologically relevant exposure levels. Moreover, when C. sonorensis were co-exposed to both viruses, we did not detect reassortment between the two viruses, despite previous in vitro findings indicating that BTV-2 and BTV-10 are able to reassort successfully. These results highlight that numerous factors, including vector species and exposure dose, may impact the in vivo replication of varying BTV strains, and underscore the complexities of BTV ecology in North America.
Collapse
Affiliation(s)
- Jennifer Kopanke
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA; (J.K.); (J.L.); (M.S.); (M.C.)
| | - Justin Lee
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA; (J.K.); (J.L.); (M.S.); (M.C.)
| | - Mark Stenglein
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA; (J.K.); (J.L.); (M.S.); (M.C.)
| | - Molly Carpenter
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA; (J.K.); (J.L.); (M.S.); (M.C.)
| | - Lee W. Cohnstaedt
- Arthropod-Borne Animal Diseases Research Unit, United States Department of Agriculture—Agricultural Research Service, Manhattan, KS 66502, USA;
| | - William C. Wilson
- National Bio and Agro-Defense Facility (NBAF), United States Department of Agriculture—Agricultural Research Service, 1880 Kimball Ave, Suite 300 CGAHR, Manhattan, KS 66502, USA;
| | - Christie Mayo
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA; (J.K.); (J.L.); (M.S.); (M.C.)
- Correspondence:
| |
Collapse
|
3
|
Wang A, Du J, Feng H, Zhou J, Chen Y, Liu Y, Jiang M, Jia R, Tian Y, Zhang G. Identification of a novel bluetongue virus 1 specific B cell epitope using monoclonal antibodies against the VP2 protein. Int J Biol Macromol 2021; 183:1393-1401. [PMID: 33984384 DOI: 10.1016/j.ijbiomac.2021.05.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 04/10/2021] [Accepted: 05/06/2021] [Indexed: 11/25/2022]
Abstract
Bluetongue (BT) is a non-contact infectious disease caused by Bluetongue virus (BTV), which can be transmitted by vector insects such as Culicoides and Aedes mosquitoes. The BTV VP2 protein encoded by the L2 gene is located at the outermost layer of the virus particle, plays a key role on mediating the adsorption and entry of virus, and it is also a main antigenic protein widely used for vaccine development. In this study, the BTV1 VP2 gene was cloned into pFastBac™Dual vector, and expressed in insect Sf21 cells. Immunized mice with purified recombinant VP2 protein can induce higher levels of antibodies. Three anti BTV1 VP2 monoclonal antibodies (mAbs) were generated (17E9C6, 17E9C8, 17E9H12), and showed high specific reactivity with recombinant VP2 protein and inactivated BTV1 virus. Finally, a novel linear B-cell epitope 296-KEPAD-300 on recombinant VP2 protein was identified by using three mAbs react with a series of continue-truncated peptides. The results of this study may provide new information on the structure and function of BTV1 VP2 protein and lay a foundation for the development of BTV1 diagnostic and prophylactic methods.
Collapse
Affiliation(s)
- Aiping Wang
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Jinran Du
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Hua Feng
- Key Laboratory of Animal Immunology of the Henan Academy of Agricultural Sciences, Zhengzhou 450002, China
| | - Jingming Zhou
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Yumei Chen
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Yankai Liu
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Min Jiang
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Rui Jia
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Yuanyuan Tian
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
| | - Gaiping Zhang
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
| |
Collapse
|
4
|
Aguilar-Vega C, Bosch J, Fernández-Carrión E, Lucientes J, Sánchez-Vizcaíno JM. Identifying Spanish Areas at More Risk of Monthly BTV Transmission with a Basic Reproduction Number Approach. Viruses 2020; 12:E1158. [PMID: 33066209 PMCID: PMC7602074 DOI: 10.3390/v12101158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 10/08/2020] [Accepted: 10/12/2020] [Indexed: 01/24/2023] Open
Abstract
Bluetongue virus (BTV) causes a disease that is endemic in Spain and its two major biological vector species, C. imicola and the Obsoletus complex species, differ greatly in their ecology and distribution. Understanding the seasonality of BTV transmission in risk areas is key to improving surveillance and control programs, as well as to better understand the pathogen transmission networks between wildlife and livestock. Here, monthly risk transmission maps were generated using risk categories based on well-known BTV R0 equations and predicted abundances of the two most relevant vectors in Spain. Previously, Culicoides spp. predicted abundances in mainland Spain and the Balearic Islands were obtained using remote sensing data and random forest machine learning algorithm. Risk transmission maps were externally assessed with the estimated date of infection of BTV-1 and BTV-4 historical outbreaks. Our results highlight the differences in risk transmission during April-October, June-August being the period with higher R0 values. Likewise, a natural barrier has been identified between northern and central-southern areas at risk that may hamper BTV spread between them. Our results can be relevant to implement risk-based interventions for the prevention, control and surveillance of BTV and other diseases shared between livestock and wildlife host populations.
Collapse
Affiliation(s)
- Cecilia Aguilar-Vega
- VISAVET Health Surveillance Centre, Animal Health Department, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain; (J.B.); (E.F.-C.); (J.M.S.-V.)
| | - Jaime Bosch
- VISAVET Health Surveillance Centre, Animal Health Department, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain; (J.B.); (E.F.-C.); (J.M.S.-V.)
| | - Eduardo Fernández-Carrión
- VISAVET Health Surveillance Centre, Animal Health Department, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain; (J.B.); (E.F.-C.); (J.M.S.-V.)
| | - Javier Lucientes
- Department of Animal Pathology (Animal Health), AgriFood Institute of Aragón IA2, Faculty of Veterinary Medicine, University of Zaragoza, 50013 Zaragoza, Spain;
| | - José Manuel Sánchez-Vizcaíno
- VISAVET Health Surveillance Centre, Animal Health Department, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain; (J.B.); (E.F.-C.); (J.M.S.-V.)
| |
Collapse
|
5
|
Veronesi E, Darpel K, Gubbins S, Batten C, Nomikou K, Mertens P, Carpenter S. Diversity of Transmission Outcomes Following Co-Infection of Sheep with Strains of Bluetongue Virus Serotype 1 and 8. Microorganisms 2020; 8:microorganisms8060851. [PMID: 32516979 PMCID: PMC7356686 DOI: 10.3390/microorganisms8060851] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 05/31/2020] [Accepted: 06/02/2020] [Indexed: 01/03/2023] Open
Abstract
Bluetongue virus (BTV) causes an economically important disease, bluetongue (BT), in susceptible ruminants and is transmitted primarily by species of Culicoides biting midges (Diptera: Ceratopogonidae). Since 2006, northern Europe has experienced multiple incursions of BTV through a variety of routes of entry, including major outbreaks of strains of BTV serotype 8 (BTV-8) and BTV serotype 1 (BTV-1), which overlapped in distribution within southern Europe. In this paper, we examined the variation in response to coinfection with strains of BTV-1 and BTV-8 using an in vivo transmission model involving Culicoides sonorensis, low passage virus strains, and sheep sourced in the United Kingdom. In the study, four sheep were simultaneously infected using BTV-8 and BTV-1 intrathoracically inoculated C. sonorensis and co-infections of all sheep with both strains were established. However, there were significant variations in both the initiation and peak levels of virus RNA detected throughout the experiment, as well as in the infection rates in the C. sonorensis that were blood-fed on experimentally infected sheep at peak viremia. This is discussed in relation to the potential for reassortment between these strains in the field and the policy implications for detection of BTV strains.
Collapse
Affiliation(s)
- Eva Veronesi
- The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK; (K.D.); (S.G.); (C.B.); (K.N.); (P.M.)
- National Centre for Vector Entomology, Institute of Parasitology, Vetsuisse Faculty, 8057 Zurich, Switzerland
- Correspondence: (E.V.); (S.C.)
| | - Karin Darpel
- The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK; (K.D.); (S.G.); (C.B.); (K.N.); (P.M.)
| | - Simon Gubbins
- The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK; (K.D.); (S.G.); (C.B.); (K.N.); (P.M.)
| | - Carrie Batten
- The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK; (K.D.); (S.G.); (C.B.); (K.N.); (P.M.)
| | - Kyriaki Nomikou
- The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK; (K.D.); (S.G.); (C.B.); (K.N.); (P.M.)
- University of Nottingham, Sutton Bonington, Leicestershire LE12 5RD, UK
| | - Peter Mertens
- The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK; (K.D.); (S.G.); (C.B.); (K.N.); (P.M.)
- University of Nottingham, Sutton Bonington, Leicestershire LE12 5RD, UK
| | - Simon Carpenter
- The Pirbright Institute, Pirbright, Surrey GU24 0NF, UK; (K.D.); (S.G.); (C.B.); (K.N.); (P.M.)
- Correspondence: (E.V.); (S.C.)
| |
Collapse
|
6
|
Yao X, Fan Q, Yao B, Lu P, Rahman SU, Chen D, Tao S. Codon Usage Bias Analysis of Bluetongue Virus Causing Livestock Infection. Front Microbiol 2020; 11:655. [PMID: 32508755 PMCID: PMC7248248 DOI: 10.3389/fmicb.2020.00655] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 03/23/2020] [Indexed: 12/22/2022] Open
Abstract
Bluetongue virus (BTV) is a double-stranded RNA virus with multiple segments and belongs to the genus Orbivirus within the family Reoviridae. BTV is spread to livestock through its dominant vector, biting midges of genus Culicoides. Although great progress has been made in genomic analyses, it is not fully understood how BTVs adapt to their hosts and evade the host's immune systems. In this study, we retrieved BTV genome sequences from the National Center for Biotechnology Information (NCBI) database and performed a comprehensive research to explore the codon usage patterns in 50 BTV strains. We used bioinformatic approaches to calculate the relative synonymous codon usage (RSCU), codon adaptation index (CAI), effective number of codons (ENC), and other indices. The results indicated that most of the overpreferred codons had A-endings, which revealed that mutational pressure was the major force shaping codon usage patterns in BTV. However, the influence of natural selection and geographical factors cannot be ignored on viral codon usage bias. Based on the RSCU values, we performed a comparative analysis between BTVs and their hosts, suggesting that BTVs were inclined to evolve their codon usage patterns that were comparable to those of their hosts. Such findings will be conducive to understanding the elements that contribute to viral evolution and adaptation to hosts.
Collapse
Affiliation(s)
- Xiaoting Yao
- State Key Laboratory of Crop Stress Biology in Arid Areas, College of Life Sciences, Northwest A&F University, Yangling, China.,College of Veterinary Medicine, Northwest A&F University, Yangling, China
| | - Qinlei Fan
- China Animal Health and Epidemiology Center, Qingdao, China
| | - Bo Yao
- State Key Laboratory of Crop Stress Biology in Arid Areas, College of Life Sciences, Northwest A&F University, Yangling, China
| | - Ping Lu
- China Animal Health and Epidemiology Center, Qingdao, China
| | - Siddiq Ur Rahman
- State Key Laboratory of Crop Stress Biology in Arid Areas, College of Life Sciences, Northwest A&F University, Yangling, China.,Department of Computer Science and Bioinformatics, Khushal Khan Khattak University, Karak, Pakistan
| | - Dekun Chen
- College of Veterinary Medicine, Northwest A&F University, Yangling, China
| | - Shiheng Tao
- State Key Laboratory of Crop Stress Biology in Arid Areas, College of Life Sciences, Northwest A&F University, Yangling, China
| |
Collapse
|
7
|
van Rijn PA. Prospects of Next-Generation Vaccines for Bluetongue. Front Vet Sci 2019; 6:407. [PMID: 31824966 PMCID: PMC6881303 DOI: 10.3389/fvets.2019.00407] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2019] [Accepted: 11/01/2019] [Indexed: 01/16/2023] Open
Abstract
Bluetongue (BT) is a haemorrhagic disease of wild and domestic ruminants with a huge economic worldwide impact on livestock. The disease is caused by BT-virus transmitted by Culicoides biting midges and disease control without vaccination is hardly possible. Vaccination is the most feasible and cost-effective way to minimize economic losses. Marketed BT vaccines are successfully used in different parts of the world. Inactivated BT vaccines are efficacious and safe but relatively expensive, whereas live-attenuated vaccines are efficacious and cheap but are unsafe because of under-attenuation, onward spread, reversion to virulence, and reassortment events. Both manufactured BT vaccines do not enable differentiating infected from vaccinated animals (DIVA) and protection is limited to the respective serotype. The ideal BT vaccine is a licensed, affordable, completely safe DIVA vaccine, that induces quick, lifelong, broad protection in all susceptible ruminant species. Promising vaccine candidates show improvement for one or more of these main vaccine standards. BTV protein vaccines and viral vector vaccines have DIVA potential depending on the selected BTV antigens, but are less effective and likely more costly per protected animal than current vaccines. Several vaccine platforms based on replicating BTV are applied for many serotypes by exchange of serotype dominant outer shell proteins. These platforms based on one BTV backbone result in attenuation or abortive virus replication and prevent disease by and spread of vaccine virus as well as reversion to virulence. These replicating BT vaccines induce humoral and T-cell mediated immune responses to all viral proteins except to one, which could enable DIVA tests. Most of these replicating vaccines can be produced similarly as currently marketed BT vaccines. All replicating vaccine platforms developed by reverse genetics are classified as genetic modified organisms. This implies extensive and expensive safety trails in target ruminant species, and acceptance by the community could be hindered. Nonetheless, several experimental BT vaccines show very promising improvements and could compete with marketed vaccines regarding their vaccine profile, but none of these next generation BT vaccines have been licensed yet.
Collapse
Affiliation(s)
- Piet A van Rijn
- Department of Virology, Wageningen Bioveterinary Research, Lelystad, Netherlands.,Department of Biochemistry, Centre for Human Metabolomics, North-West University, Potchefstroom, South Africa
| |
Collapse
|
8
|
Van den Bergh C, Coetzee P, Venter EH. Reassortment of bluetongue virus vaccine serotypes in cattle. J S Afr Vet Assoc 2018; 89:e1-e7. [PMID: 30551703 PMCID: PMC6295955 DOI: 10.4102/jsava.v89i0.1649] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 10/17/2018] [Accepted: 10/17/2018] [Indexed: 11/01/2022] Open
Abstract
Bluetongue is primarily a disease of sheep in South Africa, while cattle and goats are mostly subclinically infected. The viraemia of bluetongue virus in cattle lasts much longer than in sheep and the role of cattle in the epidemiology of bluetongue in South Africa is poorly understood. Bluetongue virus has a segmented double-stranded ribonucleic acid genome and reassortment of genomes is a common feature. The aim of the study was to investigate whether reassortment occurs between vaccine and field strains when simultaneously administered to cattle. Six cattle between the ages of 6 and 12 months were infected with five strains of modified live vaccine bluetongue virus and a virulent field isolate of bluetongue virus 4. Blood samples were subsequently collected daily from these animals from day 1 to day 39 post-inoculation. Viruses were directly isolated during viraemia from the buffy coat on Vero cells using the plaque forming unit method. Analysis of plaques indicated that no reassortants between virulent field and vaccine strains occurred and the virulent bluetongue virus 4 was identified as the predominant virus strain. However, a reassortant virus between two bluetongue virus vaccine strains was isolated from the buffy coat. Whole genome sequences from the vaccine viruses were compared to the suspected reassortant and it was found that segment 8 exchanged between the bluetongue virus 8 and bluetongue virus 9 vaccine strains. The use of the live-attenuated bluetongue virus multivalent vaccine in South Africa causes circulation of different vaccine serotypes in Culicoides spp. and susceptible hosts and cattle might provide the ideal host for reassortment to occur.
Collapse
|
9
|
Mohamed DKA, Du J, Gao S, Tian Z, Zhang G, Huang D, Du R, Kang B, Liu G, Luo J, Yin H. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep. Vet Microbiol 2018; 219:40-48. [PMID: 29778203 DOI: 10.1016/j.vetmic.2018.04.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 04/03/2018] [Accepted: 04/03/2018] [Indexed: 10/17/2022]
Abstract
Bluetongue virus (BTV), a vector-borne pathogen, is the causative agent of bluetongue disease in ruminants. In view of the recent emergence of BTV in regions previously known to be free from the disease and/or specific serotypes or strains, optimization of the currently available vaccination strategies to control the spread of vector-borne bluetongue is crucial. The main objective of the current study was to develop a subunit vaccine candidate targeting BTV-16, a strain previously isolated in China from sheep with obvious clinical signs. To this end, five polyhistidine-tagged recombinant proteins (BTV-16 VP2, VP3, VP7, NS2 and a truncated version of VP5 (VP5-41amino acids) were expressed using the baculovirus or Escherichia coli expression system for characterization of protective activity. To determine ovine and murine immune responses to the five proteins, sheep and mice were immunized twice at 4- and 2-week intervals, respectively, with one of two different protein combinations in MontanideTM ISA201 VG adjuvant or placebo. Data from the competitive enzyme linked immunosorbent assay revealed significantly higher antibody titers in immunized than control animals. Expressed VP5 and NS2 induced a protein-specific humoral response. Interestingly, a serum neutralization test against the BTV-1 serotype showed promising cross-serotype immune response by the vaccine. Based on the collective data, we suggest that these recombinant purified proteins present promising candidates for the design of effective novel vaccines against BTV.
Collapse
Affiliation(s)
- Darien Kheder Ali Mohamed
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Junzheng Du
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China.
| | - Shandian Gao
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Zhancheng Tian
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Guorui Zhang
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Dexuan Huang
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Rongsheng Du
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Biao Kang
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Guangyuan Liu
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Jianxun Luo
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China
| | - Hong Yin
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China; Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, 225009, PR China.
| |
Collapse
|
10
|
Abstract
The performance of different bluetongue control measures related to both vaccination and protection from bluetongue virus (BTV) vectors was assessed. By means of a mathematical model, it was concluded that when vaccination is applied on 95% of animals even for 3 years, bluetongue cannot be eradicated and is able to re‐emerge. Only after 5 years of vaccination, the infection may be close to the eradication levels. In the absence of vaccination, the disease can persist for several years, reaching an endemic condition with low level of prevalence of infection. Among the mechanisms for bluetongue persistence, the persistence in the wildlife, the transplacental transmission in the host, the duration of viraemia and the possible vertical transmission in vectors were assessed. The criteria of the current surveillance scheme in place in the EU for demonstration of the virus absence need revision, because it was highlighted that under the current surveillance policy bluetongue circulation might occur undetected. For the safe movement of animals, newborn ruminants from vaccinated mothers with neutralising antibodies can be considered protected against infection, although a protective titre threshold cannot be identified. The presence of colostral antibodies interferes with the vaccine immunisation in the newborn for more than 3 months after birth, whereas the minimum time after vaccination of animal to be considered immune can be up to 48 days. The knowledge about vectors ecology, mechanisms of over‐wintering and criteria for the seasonally vector‐free period was updated. Some Culicoides species are active throughout the year and an absolute vector‐free period may not exist at least in some areas in Europe. To date, there is no evidence that the use of insecticides and repellents reduce the transmission of BTV in the field, although this may reduce host/vector contact. By only using pour‐on insecticides, protection of animals is lower than the one provided by vector‐proof establishments. This publication is linked to the following EFSA Supporting Publications article: http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2017.EN-1182/full, http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2017.EN-1171/full
Collapse
|
11
|
Bessell PR, Searle KR, Auty HK, Handel IG, Purse BV, Bronsvoort BMDC. Assessing the potential for Bluetongue virus 8 to spread and vaccination strategies in Scotland. Sci Rep 2016; 6:38940. [PMID: 27958339 PMCID: PMC5154200 DOI: 10.1038/srep38940] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 11/16/2016] [Indexed: 12/11/2022] Open
Abstract
Europe has seen frequent outbreaks of Bluetongue (BT) disease since 2006, including an outbreak of BT virus serotype 8 in central France during 2015 that has continued to spread in Europe during 2016. Thus, assessing the potential for BTv-8 spread and determining the optimal deployment of vaccination is critical for contingency planning. We developed a spatially explicit mathematical model of BTv-8 spread in Scotland and explored the sensitivity of transmission to key disease spread parameters for which detailed empirical data is lacking. With parameters at mean values, there is little spread of BTv-8 in Scotland. However, under a “worst case” but still feasible scenario with parameters at the limits of their ranges and temperatures 1 °C warmer than the mean, we find extensive spread with 203,000 sheep infected given virus introduction to the south of Scotland between mid-May and mid-June. Strategically targeted vaccine interventions can greatly reduce BT spread. Specifically, despite BT having most clinical impact in sheep, we show that vaccination can have the greatest impact on reducing BTv infections in sheep when administered to cattle, which has implications for disease control policy.
Collapse
Affiliation(s)
- Paul R Bessell
- The Roslin Institute, The University of Edinburgh, Easter Bush, EH25 9RG, UK
| | - Kate R Searle
- Centre for Ecology and Hydrology, Edinburgh, EH26 0QB, UK
| | - Harriet K Auty
- Epidemiology Research Unit, Future Farming Systems Group, Scotland's Rural College (SRUC), An Lòchran, Inverness Campus, Inverness, IV2 5NA, UK
| | - Ian G Handel
- Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, EH25 9RG, UK
| | - Bethan V Purse
- Centre for Ecology and Hydrology, Wallingford, OX10 8BB, UK
| | | |
Collapse
|
12
|
Feenstra F, van Rijn PA. Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations. Crit Rev Microbiol 2016; 43:142-155. [PMID: 27800699 DOI: 10.1080/1040841x.2016.1186005] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Bluetongue virus (BTV) causes the hemorrhagic disease bluetongue (BT) in ruminants. The best way to control outbreaks is vaccination. Currently, conventionally modified-live and inactivated vaccines are commercially available, which have been successfully used to control BT, but nonetheless have their specific shortcomings. Therefore, there is a need for improved BT vaccines. The ideal BT vaccine is efficacious, safe, affordable, protective against multiple serotypes and enables the differentiation of infected from vaccinated animals. Different field situations require specific vaccine profiles. Single serotype outbreaks in former BT-free areas need rapid onset of protection against viremia of the respective serotype. In contrary, endemic multiple serotype situations require long-lasting protection against all circulating serotypes. The ideal BT vaccine for all field situations does not exist and balancing between vaccine properties is needed. Many new vaccines candidates, ranging from non-replicating subunits to replicating next-generation reverse genetics based vaccines, have been developed. Some have been tested extensively in large numbers of ruminants, whereas others were developed recently and have only been tested in vitro and in mice models. Most vaccine candidates are promising, but have their specific shortcomings and advantages. In this review, current and next-generation BT vaccines are discussed in the light of prerequisites for different field situations.
Collapse
Affiliation(s)
- Femke Feenstra
- a Department of Virology , Central Veterinary Institute of Wageningen UR , Lelystad , The Netherlands.,b Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine , Utrecht University , Utrecht , The Netherlands
| | - Piet A van Rijn
- a Department of Virology , Central Veterinary Institute of Wageningen UR , Lelystad , The Netherlands.,c Department of Biochemistry , Center for Human Metabolomics, North-West University , Potchefstroom , South Africa
| |
Collapse
|
13
|
McVey DS, MacLachlan NJ. Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective. Vector Borne Zoonotic Dis 2016; 15:385-96. [PMID: 26086559 DOI: 10.1089/vbz.2014.1698] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Bluetongue (BT) and epizootic hemorrhagic disease (EHD) are noncontagious, insect-transmitted diseases of domestic and wild ruminants caused by related but distinct viruses. There are significant gaps in our scientific knowledge and available countermeasures to control an outbreak of orbivirus-induced disease, whether BT or EHD. Both BT virus (BTV) and EHD virus (EHDV) cause hemorrhagic fevers in susceptible ruminants; however, BT is principally a disease of domestic livestock whereas EHD is principally a disease of certain species of wild, non-African ungulates, notably white-tailed deer. The live-attenuated (modified live virus [MLV]) vaccines available in the United States for use in small ruminant livestock do provide good protection against clinical disease following infection with the homologous virus serotype. Although there is increasing justification that the use of MLV vaccines should be avoided if possible, these are the only vaccines currently available in the United States. Specifically, MLVs are used in California to protect sheep against infection with BTV serotypes 10, 11, and 17, and a MLV to BTV serotype 10 is licensed for use in sheep throughout the United States. These MLV vaccines may need to continue to be used in the immediate future for protective immunization of sheep and goats against BT. There are currently no licensed vaccines available for EHD in the United States other than autogenous vaccines. If there is a need to rapidly develop a vaccine to meet an emerging crisis associated with either BTV or EHDV infections, development of an inactivated virus vaccine in a conventional adjuvanted formulation will likely be required. With two doses of vaccine (and in some instances just one dose), inactivated vaccines can provide substantial immunity to the epizootic serotype of either BTV or EHDV. This strategy is similar to that used in the 2006-2008 BTV serotype 8 outbreaks in northern Europe that provided vaccine to the field within 2 years of the initial incursion (by 2008). Further research and development are warranted to provide more efficacious and effective vaccines for control of BTV and EHDV infections.
Collapse
Affiliation(s)
- D Scott McVey
- 1 USDA, ARS , Arthropod-Borne Animal Disease Research Unit, Center for Grain and Animal Health Research, Manhattan, Kansas
| | - N James MacLachlan
- 2 Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California , Davis, California
| |
Collapse
|
14
|
Tacken MGJ, Daus FJ, Feenstra F, van Gennip RGP, van Rijn PA. Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue. Vaccine 2015; 33:5539-5545. [PMID: 26387435 DOI: 10.1016/j.vaccine.2015.09.020] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Revised: 09/04/2015] [Accepted: 09/05/2015] [Indexed: 10/23/2022]
Abstract
Recently, we have developed a novel vaccine for Bluetongue named BT Disabled Infectious Single Animal (DISA) vaccine. Due to the lack of non-essential NS3/NS3a protein, BT DISA vaccine is a replicating vaccine, but without the inherent risks of live-attenuated vaccines, such as residual virulence or reversion to virulence by mutations, reassortment with field virus, horizontal spread by vectors and vertical transmission. The immune response induced by BT DISA vaccines is rapidly induced, highly protective and serotype specific which is dependent on the immunodominant and serotype determining VP2 protein. The BT DISA vaccine platform provides the replacement of exclusively VP2 from different serotypes in order to safely formulate multivalent cocktail vaccines. The lack of NS3/NS3a directed antibodies by BT DISA vaccination enables differentiation of infected from vaccinated animals (DIVA principle). A highly conserved immunogenic site corresponding to the late domain was mapped in the N-terminal region of NS3. We here established an NS3-specific competitive ELISA (NS3 cELISA) as serological DIVA test accompanying BT DISA vaccines. To this end, NS3 protein missing putative transmembrane regions was produced in large amounts in bacteria and used as antigen in the NS3 cELISA which was investigated with a variety of sera. The NS3 cELISA displayed a high sensitivity and specificity similar to the commercially available VP7-specific cELISA. Results of previously performed vaccination-challenge trials with BT DISA vaccines clearly demonstrate the DIVA system based on the NS3 cELISA and BT vaccine free of NS3 protein.
Collapse
Affiliation(s)
- Mirriam G J Tacken
- Department of Virology, Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands
| | - Franz J Daus
- Department of Virology, Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands
| | - Femke Feenstra
- Department of Virology, Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands; Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - René G P van Gennip
- Department of Virology, Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands
| | - Piet A van Rijn
- Department of Virology, Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands; Department of Biochemistry, Centre for Human Metabonomics, North-West University, Potchefstroom, South Africa.
| |
Collapse
|
15
|
Kyriakis CS, Billinis C, Papadopoulos E, Vasileiou NGC, Athanasiou LV, Fthenakis GC. Bluetongue in small ruminants: An opinionated review, with a brief appraisal of the 2014 outbreak of the disease in Greece and the south-east Europe. Vet Microbiol 2015; 181:66-74. [PMID: 26304745 DOI: 10.1016/j.vetmic.2015.08.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Bluetongue is an arthropod-borne viral disease of ruminants, especially of sheep, caused by Bluetongue virus, which belongs to the genus Orbivirus of the family Reoviridae and is classified into 26 antigenically distinct serotypes. Once thought to be restricted in Africa and parts of the Middle East, bluetongue has now become a concern in sheep-rearing countries around the world. In the past 10 years, severe outbreaks have occurred in Europe with important economic consequences; of these, the 2006-20008 outbreak in Europe was caused by a serotype 8 strain and the 2014 outbreak in Greece and the other countries of south-east Europe was caused by a serotype 4 strain, suggested to be a reassortant strain with genome segments from lineages of serotype 1, 2 and 4. Immunisation campaigns can be implemented for successful control and limiting of the disease. Nevertheless, in both of the above outbreaks, late application of vaccinations led to a wide spread of the disease, which subsequently resulted in significant losses in livestock in the affected regions. In view of that, standardisation of control measures in the future will be beneficial for efficiently limiting outbreaks of the disease.
Collapse
Affiliation(s)
- C S Kyriakis
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
| | - C Billinis
- Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece
| | - E Papadopoulos
- School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - N G C Vasileiou
- Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece
| | - L V Athanasiou
- Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece
| | - G C Fthenakis
- Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece
| |
Collapse
|
16
|
Anderson J, Hägglund S, Bréard E, Riou M, Zohari S, Comtet L, Olofson AS, Gélineau R, Martin G, Elvander M, Blomqvist G, Zientara S, Valarcher JF. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle. Vaccine 2014; 32:6614-21. [PMID: 25312275 DOI: 10.1016/j.vaccine.2014.09.066] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Revised: 09/23/2014] [Accepted: 09/29/2014] [Indexed: 11/18/2022]
Abstract
Bluetongue virus (BTV) infections in ruminants pose a permanent agricultural threat since new serotypes are constantly emerging in new locations. Clinical disease is mainly observed in sheep, but cattle were unusually affected during an outbreak of BTV seroype 8 (BTV-8) in Europe. We previously developed an experimental vaccine based on recombinant viral protein 2 (VP2) of BTV-8 and non-structural proteins 1 (NS1) and NS2 of BTV-2, mixed with an immunostimulating complex (ISCOM)-matrix adjuvant. We demonstrated that bovine immune responses induced by this vaccine were as good or superior to those induced by a classic commercial inactivated vaccine. In this study, we evaluated the protective efficacy of the experimental vaccine in cattle and, based on the detection of VP7 antibodies, assessed its DIVA compliancy following virus challenge. Two groups of BTV-seronegative calves were subcutaneously immunized twice at a 3-week interval with the subunit vaccine (n=6) or with adjuvant alone (n=6). Following BTV-8 challenge 3 weeks after second immunization, controls developed viremia and fever associated with other mild clinical signs of bluetongue disease, whereas vaccinated animals were clinically and virologically protected. The vaccine-induced protection was likely mediated by high virus-neutralizing antibody titers directed against VP2 and perhaps by cellular responses to NS1 and NS2. T lymphocyte responses were cross-reactive between BTV-2 and BTV-8, suggesting that NS1 and NS2 may provide the basis of an adaptable vaccine that can be varied by using VP2 of different serotypes. The detection of different levels of VP7 antibodies in vaccinated animals and controls after challenge suggested a compliancy between the vaccine and the DIVA companion test. This BTV subunit vaccine is a promising candidate that should be further evaluated and developed to protect against different serotypes.
Collapse
Affiliation(s)
- Jenna Anderson
- Swedish University of Agricultural Sciences, Host Pathogen Interaction Group, Department of Clinical Sciences, Almas allé 4 C, Uppsala, Sweden
| | - Sara Hägglund
- Swedish University of Agricultural Sciences, Host Pathogen Interaction Group, Department of Clinical Sciences, Almas allé 4 C, Uppsala, Sweden
| | - Emmanuel Bréard
- ANSES, UMR Virologie 1161 ANSES/INRA/ENVA, 23 Avenue Général de Gaulle, Maisons-Alfort, France
| | - Mickaël Riou
- INRA, Centre Val de Loire, UE-1277 Plateforme d'Infectiologie expérimentale (PFIE), Route de Crotelles, Nouzilly, France
| | - Siamak Zohari
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Loic Comtet
- IdVet, 167 rue Mehdi Ben Barka, Montpellier, France
| | - Ann-Sophie Olofson
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Robert Gélineau
- INRA, Centre Val de Loire, UE-1277 Plateforme d'Infectiologie expérimentale (PFIE), Route de Crotelles, Nouzilly, France
| | - Guillaume Martin
- INRA, Centre Val de Loire, UE-1277 Plateforme d'Infectiologie expérimentale (PFIE), Route de Crotelles, Nouzilly, France
| | - Marianne Elvander
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Gunilla Blomqvist
- National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden
| | - Stéphan Zientara
- ANSES, UMR Virologie 1161 ANSES/INRA/ENVA, 23 Avenue Général de Gaulle, Maisons-Alfort, France
| | - Jean Francois Valarcher
- Swedish University of Agricultural Sciences, Host Pathogen Interaction Group, Department of Clinical Sciences, Almas allé 4 C, Uppsala, Sweden; National Veterinary Institute, Department of Virology, Immunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden.
| |
Collapse
|
17
|
Feenstra F, van Gennip RGP, Maris-Veldhuis M, Verheij E, van Rijn PA. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge. J Gen Virol 2014; 95:2019-2029. [DOI: 10.1099/vir.0.065615-0] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Bluetongue is a disease in ruminants caused by the bluetongue virus (BTV), and is spread by Culicoides biting midges. Bluetongue outbreaks cause huge economic losses and death in sheep in several parts of the world. The most effective measure to control BTV is vaccination. However, both commercially available vaccines and recently developed vaccine candidates have several shortcomings. Therefore, we generated and tested next-generation vaccines for bluetongue based on the backbone of a laboratory-adapted strain of BTV-1, avirulent BTV-6 or virulent BTV-8. All vaccine candidates were serotyped with VP2 of BTV-8 and did not express NS3/NS3a non-structural proteins, due to induced deletions in the NS3/NS3a ORF. Sheep were vaccinated once with one of these vaccine candidates and were challenged with virulent BTV-8 3 weeks after vaccination. The NS3/NS3a knockout mutation caused complete avirulence for all three BTV backbones, including for virulent BTV-8, indicating that safety is associated with the NS3/NS3a knockout phenotype. Viraemia of vaccine virus was not detected using sensitive PCR diagnostics. Apparently, the vaccine viruses replicated only locally, which will minimize spread by the insect vector. In particular, the vaccine based on the BTV-6 backbone protected against disease and prevented viraemia of challenge virus, showing the efficacy of this vaccine candidate. The lack of NS3/NS3a expression potentially enables the differentiation of infected from vaccinated animals, which is important for monitoring virus spread in vaccinated livestock. The disabled infectious single-animal vaccine for bluetongue presented here is very promising and will be the subject of future studies.
Collapse
Affiliation(s)
- Femke Feenstra
- Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
- Department of Virology, Central Veterinary Institute of Wageningen UR (CVI), Lelystad, The Netherlands
| | - René G. P. van Gennip
- Department of Virology, Central Veterinary Institute of Wageningen UR (CVI), Lelystad, The Netherlands
| | - Mieke Maris-Veldhuis
- Department of Virology, Central Veterinary Institute of Wageningen UR (CVI), Lelystad, The Netherlands
| | - Eline Verheij
- Department of Virology, Central Veterinary Institute of Wageningen UR (CVI), Lelystad, The Netherlands
| | - Piet A. van Rijn
- Department of Biochemistry, Centre for Human Metabonomics, North-West University, Potchefstroom, South Africa
- Department of Virology, Central Veterinary Institute of Wageningen UR (CVI), Lelystad, The Netherlands
| |
Collapse
|
18
|
A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus. J Virol 2014; 88:12222-32. [PMID: 25142610 PMCID: PMC4248921 DOI: 10.1128/jvi.02183-14] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Bluetongue is one of the major infectious diseases of ruminants and is caused by bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV. The advent of synthetic biology approaches and the development of reverse genetics systems has allowed the rapid and reliable design and production of pathogen genomes which can be subsequently manipulated for vaccine production. We describe BTV vaccines based on “synthetic” viruses in which the outer core proteins of different BTV serotypes are incorporated into a common tissue-culture-adapted backbone. As a means of validation for this approach, we selected two BTV-8 synthetic reassortants and demonstrated their ability to protect sheep against virulent BTV-8 challenge. In addition to further highlight the possibilities of genome manipulation for vaccine production, we also designed and rescued a synthetic BTV chimera containing a VP2 protein, including regions derived from both BTV-1 and BTV-8. Interestingly, while the parental viruses were neutralized only by homologous antisera, the chimeric proteins could be neutralized by both BTV-1 and BTV-8 antisera. These data suggest that neutralizing epitopes are present in different areas of the BTV VP2 and likely “bivalent” strains eliciting neutralizing antibodies for multiple strains can be obtained. IMPORTANCE Overall, this vaccine platform can significantly reduce the time taken from the identification of new BTV strains to the development and production of new vaccines, since the viral genomes of these viruses can be entirely synthesized in vitro. In addition, these vaccines can be brought quickly into the market because they alter the approach, but not the final product, of existing commercial products.
Collapse
|
19
|
Abstract
Bluetongue is a major infectious disease of ruminants caused by bluetongue virus (BTV), an arbovirus transmitted by Culicoides. Here, we assessed virus and host factors influencing the clinical outcome of BTV infection using a single experimental framework. We investigated how mammalian host species, breed, age, BTV serotypes, and strains within a serotype affect the clinical course of bluetongue. Results obtained indicate that in small ruminants, there is a marked difference in the susceptibility to clinical disease induced by BTV at the host species level but less so at the breed level. No major differences in virulence were found between divergent serotypes (BTV-8 and BTV-2). However, we observed striking differences in virulence between closely related strains of the same serotype collected toward the beginning and the end of the European BTV-8 outbreak. As observed previously, differences in disease severity were also observed when animals were infected with either blood from a BTV-infected animal or from the same virus isolated in cell culture. Interestingly, with the exception of two silent mutations, full viral genome sequencing showed identical consensus sequences of the virus before and after cell culture isolation. However, deep sequencing analysis revealed a marked decrease in the genetic diversity of the viral population after passaging in mammalian cells. In contrast, passaging in Culicoides cells increased the overall number of low-frequency variants compared to virus never passaged in cell culture. Thus, Culicoides might be a source of new viral variants, and viral population diversity can be another factor influencing BTV virulence. IMPORTANCE Bluetongue is one of the major infectious diseases of ruminants. It is caused by an arbovirus known as bluetongue virus (BTV). The clinical outcome of BTV infection is extremely variable. We show that there are clear links between the severity of bluetongue and the mammalian host species infected, while at the breed level differences were less evident. No differences were observed in the virulence of two different BTV serotypes (BTV-8 and BTV-2). In contrast, we show that the European BTV-8 strain isolated at the beginning of the bluetongue outbreak in 2006 was more virulent than a strain isolated toward the end of the outbreak. In addition, we show that there is a link between the variability of the BTV population as a whole and virulence, and our data also suggest that Culicoides cells might function as an “incubator” of viral variants.
Collapse
|
20
|
Coetzee P, van Vuuren M, Venter EH, Stokstad M. A review of experimental infections with bluetongue virus in the mammalian host. Virus Res 2014; 182:21-34. [PMID: 24462840 PMCID: PMC7132480 DOI: 10.1016/j.virusres.2013.12.044] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 12/27/2013] [Accepted: 12/31/2013] [Indexed: 11/23/2022]
Abstract
Experimental infection studies with bluetongue virus (BTV) in the mammalian host have a history that stretches back to the late 18th century. Studies in a wide range of ruminant and camelid species as well as mice have been instrumental in understanding BTV transmission, bluetongue (BT) pathogenicity/pathogenesis, viral virulence, the induced immune response, as well as reproductive failures associated with BTV infection. These studies have in many cases been complemented by in vitro studies with BTV in different cell types in tissue culture. Together these studies have formed the basis for the understanding of BTV-host interaction and have contributed to the design of successful control strategies, including the development of effective vaccines. This review describes some of the fundamental and contemporary infection studies that have been conducted with BTV in the mammalian host and provides an overview of the principal animal welfare issues that should be considered when designing experimental infection studies with BTV in in vivo infection models. Examples are provided from the authors' own laboratory where the three Rs (replacement, reduction and refinement) have been implemented in the design of experimental infection studies with BTV in mice and goats. The use of the ARRIVE guidelines for the reporting of data from animal infection studies is emphasized.
Collapse
Affiliation(s)
- Peter Coetzee
- Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, Onderstepoort, Pretoria 0110, South Africa; Department of Production Animal Clinical Sciences, Norwegian School of Veterinary Science, P. O. Box 8146 Dep., N-0033 Oslo, Norway.
| | - Moritz van Vuuren
- Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, Onderstepoort, Pretoria 0110, South Africa.
| | - Estelle H Venter
- Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, Onderstepoort, Pretoria 0110, South Africa.
| | - Maria Stokstad
- Department of Production Animal Clinical Sciences, Norwegian School of Veterinary Science, P. O. Box 8146 Dep., N-0033 Oslo, Norway.
| |
Collapse
|
21
|
Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2014; 21:443-52. [PMID: 24451327 DOI: 10.1128/cvi.00776-13] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Bluetongue virus (BTV) causes bluetongue disease, a vector-borne disease of ruminants. The recent northerly spread of BTV serotype 8 in Europe resulted in outbreaks characterized by clinical signs in cattle, including unusual teratogenic effects. Vaccination has been shown to be crucial for controlling the spread of vector-borne diseases such as BTV. With the aim of developing a novel subunit vaccine targeting BTV-8 that allows differentiation of infected from vaccinated animals, five His-tagged recombinant proteins, VP2 and VP5 of BTV-8 and NS1, NS2, and NS3 of BTV-2, were expressed in baculovirus or Escherichia coli expression systems for further study. Optimized purification protocols were determined for VP2, NS1, NS2, and NS3, which remained stable for detection for at least 560 to 610 days of storage at +4°C or -80°C, and Western blotting using sera from vaccinated or experimentally infected cattle indicated that VP2 and NS2 were recognized by BTV-specific antibodies. To characterize murine immune responses to the four proteins, mice were subcutaneously immunized twice at a 4-week interval with one of three protein combinations plus immunostimulating complex ISCOM-Matrix adjuvant or with ISCOM-Matrix alone (n = 6 per group). Significantly higher serum IgG antibody titers specific for VP2 and NS2 were detected in immunized mice than were detected in controls. VP2, NS1, and NS2 but not NS3 induced specific lymphocyte proliferative responses upon restimulation of spleen cells from immunized mice. The data suggest that these recombinant purified proteins, VP2, NS1, and NS2, could be an important part of a novel vaccine design against BTV-8.
Collapse
|
22
|
Maan S, Ghosh A, Batra K, Kumar A, Maan NS. Genomic diversity among eastern and western topotypes of bluetongue virus serotype 16 based on whole genome sequence analysis. Vet World 2013. [DOI: 10.14202/vetworld.2013.960-962] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
23
|
Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2013; 20:1115-22. [PMID: 23720365 DOI: 10.1128/cvi.00229-13] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Bluetongue virus (BTV), the causative agent of bluetongue in ruminants, is an emerging virus in northern Europe. The 2006 outbreak of BTV serotype 8 (BTV-8) in Europe was marked by an unusual teratogenic effect and a high frequency of clinical signs in cattle. Conventional control strategies targeting small ruminants were therefore extended to include cattle. Since cattle were not routinely vaccinated before 2006, the immune responses to BTV have not been studied extensively in this species. With the aims of developing a subunit vaccine against BTV-8 for differentiation between infected and vaccinated animals based on viral protein 7 (VP7) antibody detection and of improving the current understanding of the immunogenicity of BTV proteins in cattle, the immune responses induced by recombinant VP2 (BTV-8) and nonstructural protein 1 (NS1) and NS2 (BTV-2) were studied. Cows were immunized twice (with a 3-week interval) with the experimental vaccine, a commercial inactivated vaccine, or a placebo. The two vaccines induced similar neutralizing antibody responses to BTV-8. Furthermore, the antibody responses detected against VP2, NS1, and NS2 were strongest in the animals immunized with the experimental vaccine, and for the first time, a serotype cross-reactive antibody response to NS2 was shown in cattle vaccinated with the commercial vaccine. The two vaccines evoked measurable T cell responses against NS1, thereby supporting a bovine cross-reactive T cell response. Finally, VP7 seroconversion was observed after vaccination with the commercial vaccine, as in natural infections, but not after vaccination with the experimental vaccine, indicating that the experimental vaccine may allow the differentiation of vaccinated animals from infected animals regardless of BTV serotype. The experimental vaccine will be further evaluated during a virulent challenge in a high-containment facility.
Collapse
|
24
|
Coetzee P, Stokstad M, Venter EH, Myrmel M, Van Vuuren M. Bluetongue: a historical and epidemiological perspective with the emphasis on South Africa. Virol J 2012; 9:198. [PMID: 22973992 PMCID: PMC3492172 DOI: 10.1186/1743-422x-9-198] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2012] [Accepted: 08/29/2012] [Indexed: 02/08/2023] Open
Abstract
Bluetongue (BT) is a non-contagious, infectious, arthropod transmitted viral disease of domestic and wild ruminants that is caused by the bluetongue virus (BTV), the prototype member of the Orbivirus genus in the family Reoviridae. Bluetongue was first described in South Africa, where it has probably been endemic in wild ruminants since antiquity. Since its discovery BT has had a major impact on sheep breeders in the country and has therefore been a key focus of research at the Onderstepoort Veterinary Research Institute in Pretoria, South Africa. Several key discoveries were made at this Institute, including the demonstration that the aetiological agent of BT was a dsRNA virus that is transmitted by Culicoides midges and that multiple BTV serotypes circulate in nature. It is currently recognized that BT is endemic throughout most of South Africa and 22 of the 26 known serotypes have been detected in the region. Multiple serotypes circulate each vector season with the occurrence of different serotypes depending largely on herd-immunity. Indigenous sheep breeds, cattle and wild ruminants are frequently infected but rarely demonstrate clinical signs, whereas improved European sheep breeds are most susceptible. The immunization of susceptible sheep remains the most effective and practical control measure against BT. In order to protect sheep against multiple circulating serotypes, three pentavalent attenuated vaccines have been developed. Despite the proven efficacy of these vaccines in protecting sheep against the disease, several disadvantages are associated with their use in the field.
Collapse
Affiliation(s)
- Peter Coetzee
- Department of Veterinary Tropical Diseases, Faculty of Veterinary Medicine, University of Pretoria, Private Bag X04, Onderstepoort, Pretoria 0110, South Africa.
| | | | | | | | | |
Collapse
|
25
|
Coetzee P, Van Vuuren M, Stokstad M, Myrmel M, Venter EH. Bluetongue virus genetic and phenotypic diversity: towards identifying the molecular determinants that influence virulence and transmission potential. Vet Microbiol 2012; 161:1-12. [PMID: 22835527 DOI: 10.1016/j.vetmic.2012.07.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2012] [Revised: 06/22/2012] [Accepted: 07/02/2012] [Indexed: 12/23/2022]
Abstract
Bluetongue virus (BTV) is the prototype member of the Orbivirus genus in the family Reoviridae and is the aetiological agent of the arthropod transmitted disease bluetongue (BT) that affects both ruminant and camelid species. The disease is of significant global importance due to its economic impact and effect on animal welfare. Bluetongue virus, a dsRNA virus, evolves through a process of quasispecies evolution that is driven by genetic drift and shift as well as intragenic recombination. Quasispecies evolution coupled with founder effect and evolutionary selective pressures has over time led to the establishment of genetically distinct strains of the virus in different epidemiological systems throughout the world. Bluetongue virus field strains may differ substantially from each other with regards to their phenotypic properties (i.e. virulence and/or transmission potential). The intrinsic molecular determinants that influence the phenotype of BTV have not clearly been characterized. It is currently unclear what contribution each of the viral genome segments have in determining the phenotypic properties of the virus and it is also unknown how genetic variability in the individual viral genes and their functional domains relate to differences in phenotype. In order to understand how genetic variation in particular viral genes could potentially influence the phenotypic properties of the virus; a closer understanding of the BTV virion, its encoded proteins and the evolutionary mechanisms that shape the diversity of the virus is required. This review provides a synopsis of these issues and highlights some of the studies that have been conducted on BTV and the closely related African horse sickness virus (AHSV) that have contributed to ongoing attempts to identify the molecular determinants that influence the virus' phenotype. Different strategies that can be used to generate BTV mutants in vitro and methods through which the causality between particular genetic modifications and changes in phenotype may be determined are also described. Finally examples are highlighted where a clear understanding of the molecular determinants that influence the phenotype of the virus may have contributed to risk assessment and mitigation strategies during recent outbreaks of BT in Europe.
Collapse
Affiliation(s)
- Peter Coetzee
- Department of Veterinary Tropical Diseases, University of Pretoria, Private Bag X04, Onderstepoort, Pretoria, 0110, South Africa.
| | | | | | | | | |
Collapse
|
26
|
Stewart M, Dovas CI, Chatzinasiou E, Athmaram TN, Papanastassopoulou M, Papadopoulos O, Roy P. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 2012; 30:2131-9. [PMID: 22285887 DOI: 10.1016/j.vaccine.2012.01.042] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2011] [Revised: 01/10/2012] [Accepted: 01/13/2012] [Indexed: 12/31/2022]
Abstract
There have been multiple separate outbreaks of Bluetongue (BT) disease of ruminants in Europe since 1998, often entering via the Mediterranean countries of Italy, Spain and Greece. BT is caused by an orbivirus, Bluetongue virus (BTV), a member of the family Reoviridae. BTV is a non-enveloped double-capsid virus, which encodes 7 structural proteins (VP1-VP7) and several non-structural proteins (NS1, NS2, NS3/3a and NS4) from ten double-stranded RNA segments of the genome. In this report, we have prepared BTV virus-like particles (VLPs, composed of VP2, VP3, VP5 and VP7) and sub-viral, inner core-like particles (CLPs, VP3 and VP7) using a recombinant baculovirus expression system. We compared the protective efficacy of VLPs and CLPs in sheep and investigated the importance of geographical lineages of BTV in the development of vaccines. The Greek crossbred Karagouniko sheep, which display mild to sub-clinical BT, were vaccinated with VLPs or CLPs of BTV-1, derived from western lineage and were challenged with virulent BTV-1 from an eastern lineage. All VLP-vaccinated animals developed a neutralising antibody response to BTV-1 from both lineages prior to challenge. Moreover, post-challenged animals had no clinical manifestation or viraemia and the challenged virus replication was completely inhibited. In contrast, CLP-vaccinated animals did not induce any neutralising antibody response but developed the group specific VP7 antibodies. CLPs also failed to prevent the clinical manifestation and virus replication, but in comparison to controls, the severity of disease manifestation and viraemia was mitigated. The data demonstrated that the outer capsid was essential for complete protection, while the geographical origin of the BTV was not critical for development of a serotype specific vaccine.
Collapse
Affiliation(s)
- M Stewart
- Department of Infectious Diseases, London School of Hygiene and Tropical Medicine, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Bluetongue is a major infectious disease of ruminants that is caused by bluetongue virus (BTV). In this study, we analyzed virulence and genetic differences of (i) three BTV field strains from Italy maintained at either a low (L strains) or high (H strains) passage number in cell culture and (ii) three South African "reference" wild-type strains and their corresponding live attenuated vaccine strains. The Italian BTV L strains, in general, were lethal for both newborn NIH-Swiss mice inoculated intracerebrally and adult type I interferon receptor-deficient (IFNAR(-/-)) mice, while the virulence of the H strains was attenuated significantly in both experimental models. Similarly, the South African vaccine strains were not pathogenic for IFNAR(-/-) mice, while the corresponding wild-type strains were virulent. Thus, attenuation of the virulence of the BTV strains used in this study is not mediated by the presence of an intact interferon system. No clear distinction in virulence was observed for the South African BTV strains in newborn NIH-Swiss mice. Full genomic sequencing revealed relatively few amino acid substitutions, scattered in several different viral proteins, for the strains found to be attenuated in mice compared to the pathogenic related strains. However, only the genome segments encoding VP1, VP2, and NS2 consistently showed nonsynonymous changes between all virulent and attenuated strain pairs. This study established an experimental platform for investigating the determinants of BTV virulence. Future studies using reverse genetics will allow researchers to precisely map and "weight" the relative influences of the various genome segments and viral proteins on BTV virulence.
Collapse
|
28
|
Brenner J, Batten C, Yadin H, Bumbarov V, Friedgut O, Rotenberg D, Golender N, Oura CAL. Clinical syndromes associated with the circulation of multiple serotypes of bluetongue virus in dairy cattle in Israel. Vet Rec 2011; 169:389. [PMID: 21862467 DOI: 10.1136/vr.d4629] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
From 2008 to 2011, seven distinct bluetongue virus (BTV) serotypes (BTV-2, BTV-4, BTV-5, BTV-8, BTV-15, BTV-16 and BTV-24) have been identified to be circulating in diseased sheep and cattle in Israel. This paper describes the array of clinical manifestations caused by BTV in cattle in Israel. Each set of clinical manifestations has been categorised as a syndrome and six distinct clinical syndromes have been observed in dairy cattle: 'footrot-like syndrome', 'sore nose syndrome', 'subcutaneous emphysema syndrome', 'red/rough udder syndrome', 'bluetongue/epizootic haemorrhagic disease systemic syndrome' and 'maladjustment syndrome'.
Collapse
Affiliation(s)
- J Brenner
- Kimron Veterinary Institute, PO Box 12, Beit Dagan 50250, Israel.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Guis H, Caminade C, Calvete C, Morse AP, Tran A, Baylis M. Modelling the effects of past and future climate on the risk of bluetongue emergence in Europe. J R Soc Interface 2011; 9:339-50. [PMID: 21697167 PMCID: PMC3243388 DOI: 10.1098/rsif.2011.0255] [Citation(s) in RCA: 111] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Vector-borne diseases are among those most sensitive to climate because the ecology of vectors and the development rate of pathogens within them are highly dependent on environmental conditions. Bluetongue (BT), a recently emerged arboviral disease of ruminants in Europe, is often cited as an illustration of climate's impact on disease emergence, although no study has yet tested this association. Here, we develop a framework to quantitatively evaluate the effects of climate on BT's emergence in Europe by integrating high-resolution climate observations and model simulations within a mechanistic model of BT transmission risk. We demonstrate that a climate-driven model explains, in both space and time, many aspects of BT's recent emergence and spread, including the 2006 BT outbreak in northwest Europe which occurred in the year of highest projected risk since at least 1960. Furthermore, the model provides mechanistic insight into BT's emergence, suggesting that the drivers of emergence across Europe differ between the South and the North. Driven by simulated future climate from an ensemble of 11 regional climate models, the model projects increase in the future risk of BT emergence across most of Europe with uncertainty in rate but not in trend. The framework described here is adaptable and applicable to other diseases, where the link between climate and disease transmission risk can be quantified, permitting the evaluation of scale and uncertainty in climate change's impact on the future of such diseases.
Collapse
Affiliation(s)
- Helene Guis
- Liverpool University Climate and Infectious Diseases of Animals (Lucinda) Group, Faculty of Veterinary Science, Leahurst Campus, University of Liverpool, Neston CH64 7TE, UK
| | | | | | | | | | | |
Collapse
|
30
|
Nusinovici S, Seegers H, Joly A, Beaudeau F, Fourichon C. A side effect of decreased fertility associated with vaccination against bluetongue virus serotype 8 in Holstein dairy cows. Prev Vet Med 2011; 101:42-50. [PMID: 21676477 DOI: 10.1016/j.prevetmed.2011.05.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2011] [Revised: 04/25/2011] [Accepted: 05/18/2011] [Indexed: 12/01/2022]
Abstract
Inactivated virus vaccines have been widely used to control bluetongue after introduction of serotype 8 of the bluetongue virus (BTV) in northern Europe in 2006. To evaluate vaccination, quantitative knowledge of its possible side effects is needed. One current adverse reaction with inactivated vaccines is a rise in body temperature, which could reduce cow reproductive performance. The objective of this study was to quantify a possible side effect of vaccination on fertility before the implantation of the embryo of dairy cows under field conditions. The study was performed on herds that were not exposed to BTV. Fertility was assessed by return-to-service following artificial insemination (AI). Biological assumptions for a possible side effect of vaccination were conception failure and embryonic death. Associations between return-to-service rates and vaccine injections were assessed using mixed-logistic regression models and survival analysis. Two models were considered: a 3-week-return-to-service model comparing cows vaccinated between 3 days before and 16 days after AI and unvaccinated cows (assuming an effect on conception failure or early embryonic death), and a 90-day-return-to-service model comparing cows vaccinated between 3 days before and 42 days after AI and unvaccinated cows (assuming an effect on conception failure, early or late embryonic death). Only cows receiving a second vaccine injection between 2 and 7 days after AI had a significantly higher risk of 3-week-return-to-service (RR=1.19 [1.07-1.33]). This corresponds to an increase of return-to-service by 4 percentage points. A side effect of vaccination could be due to early embryonic death. The slight side effect on fertility associated with vaccination was low compared to effects of BTV-8 exposure on fertility.
Collapse
Affiliation(s)
- Simon Nusinovici
- Oniris, UMR1300 Bio-agression, Epidémiologie et Analyse de Risque, La Chantrerie, BP 40706, F-44307 Nantes, France.
| | | | | | | | | |
Collapse
|
31
|
|
32
|
Eschbaumer M, Hoffmann B, Moss A, Savini G, Leone A, König P, Zemke J, Conraths F, Beer M. Emergence of bluetongue virus serotype 6 in Europe—German field data and experimental infection of cattle. Vet Microbiol 2010; 143:189-95. [DOI: 10.1016/j.vetmic.2009.11.040] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2009] [Revised: 11/16/2009] [Accepted: 11/26/2009] [Indexed: 11/28/2022]
|
33
|
Stewart M, Bhatia Y, Athmaran T, Noad R, Gastaldi C, Dubois E, Russo P, Thiéry R, Sailleau C, Bréard E, Zientara S, Roy P. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. Vaccine 2010; 28:3047-54. [DOI: 10.1016/j.vaccine.2009.10.072] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2009] [Revised: 10/05/2009] [Accepted: 10/14/2009] [Indexed: 11/27/2022]
|
34
|
Umeshappa CS, Singh KP, Nanjundappa RH, Pandey AB. Apoptosis and immuno-suppression in sheep infected with bluetongue virus serotype-23. Vet Microbiol 2010; 144:310-8. [PMID: 20347236 DOI: 10.1016/j.vetmic.2010.02.033] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2009] [Revised: 02/13/2010] [Accepted: 02/23/2010] [Indexed: 11/25/2022]
Abstract
The role of apoptosis in pathogenesis of bluetongue (BT) has been suggested from various in vitro studies. However, to date, no clear data are available regarding BTV-induced apoptosis and its consequences in natural host, sheep. In the present study, bluetongue virus (BTV)-induced apoptosis was studied in sheep blood and splenic mononuclear cells by analyzing annexin(+)-propidium iodide(-) early apoptotic cells, DNA ladder pattern, and caspase-3 gene expression. The onset of apoptosis and lymphocyte depletion in viraemic phase and IFN-alpha response indicated the involvement of BTV and IFN-alpha in the pathogenesis of BT. The development of Pasteurella pneumonia in 4 of 7 infected sheep during the experiment pointed to possible BTV-induced immuno-suppression and predisposition to secondary microbial infections. These results have significant implications not only in understanding immuno-pathological consequences but also in studying interactions of BTV with host cells.
Collapse
Affiliation(s)
- Channakeshava Sokke Umeshappa
- Center for Animal Disease Research and Diagnosis, Pathology Laboratory, Indian Veterinary Research Institute, Izatnagar 243122, India.
| | | | | | | |
Collapse
|
35
|
Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009; 8:1379-98. [PMID: 19803760 DOI: 10.1586/erv.09.81] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Complex antigen structures currently represent the most-studied approach for prophylactic as well as therapeutic vaccines. Different types of complex vaccines, including virus-like particles and virosomes, have been developed depending on the nature of the viral pathogen they are trying to replicate (enveloped vs naked) or the modality to express antigenic epitopes (i.e., the binding of envelope protein on liposomic structures). The complex structure of these vaccines provides them with some adjuvanted properties, not uniformly present for all virus-like particle types. The further inclusion of specific adjuvants in vaccine preparations can modify the presentation modality of such particles to the immune system with a specific Th1 versus Th2 polarization efficacy. A paradigm of the relevance of these new adjuvants are the immunological results obtained with the inclusion of monophosphoryl lipid A adjuvant in the formulation of L1-based human papillomavirus-naked virus-like particles to reduce a Th1 cellular immunity impairment, peculiar for alum-derived adjuvants, along with the induction of highly enhanced humoral and memory B-cellular immunity.
Collapse
Affiliation(s)
- Franco Maria Buonaguro
- Molecular Biology and Viral Oncology, Department of Experimental Oncology, Istituto Nazionale Tumori Fond Pascale, Via Mariano Semmola 142, 80131 Napoli, Italy.
| | | | | |
Collapse
|
36
|
Wilson AJ, Mellor PS. Bluetongue in Europe: past, present and future. Philos Trans R Soc Lond B Biol Sci 2009; 364:2669-81. [PMID: 19687037 DOI: 10.1098/rstb.2009.0091] [Citation(s) in RCA: 263] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The recent arrival in Northern and Western (NW) Europe of bluetongue virus (BTV), which causes the ruminant disease 'bluetongue', has raised the profile of this vector-borne ruminant disease and sparked discussions on the reasons for its sudden emergence so far north. This expansion has not happened in isolation and the disease has been expanding into Southern and Eastern Europe for the last decade. This shifting disease distribution is being facilitated by a number of different introduction mechanisms including the movement of infected livestock, the passive movement of infected Culicoides on the wind and, in NW Europe, an unknown route of introduction. The expansion of BTV in Europe has forced a re-evaluation of the importance of Palaearctic Culicoides species in transmission, as well as the importance of secondary transmission routes, such as transplacental transmission, in facilitating the persistence of the virus. The current European outbreak of BTV-8 is believed to have caused greater economic damage than any previous single-serotype outbreak. Although attempts are being made to improve the capacity of European countries to cope with future BTV incursions, the options available are limited by a lack of basic entomological data and limited virological surveillance.
Collapse
Affiliation(s)
- Anthony J Wilson
- Institute for Animal Health Pirbright Laboratory, Pirbright, Woking, Surrey GU24 0NF, UK.
| | | |
Collapse
|
37
|
Szmaragd C, Wilson AJ, Carpenter S, Wood JLN, Mellor PS, Gubbins S. A modeling framework to describe the transmission of bluetongue virus within and between farms in Great Britain. PLoS One 2009; 4:e7741. [PMID: 19890400 PMCID: PMC2767512 DOI: 10.1371/journal.pone.0007741] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2009] [Accepted: 10/15/2009] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Recently much attention has been given to developing national-scale micro-simulation models for livestock diseases that can be used to predict spread and assess the impact of control measures. The focus of these models has been on directly transmitted infections with little attention given to vector-borne diseases such as bluetongue, a viral disease of ruminants transmitted by Culicoides biting midges. Yet BT has emerged over the past decade as one of the most important diseases of livestock. METHODOLOGY/PRINCIPAL FINDINGS We developed a stochastic, spatially-explicit, farm-level model to describe the spread of bluetongue virus (BTV) within and between farms. Transmission between farms was modeled by a generic kernel, which includes both animal and vector movements. Once a farm acquired infection, the within-farm dynamics were simulated based on the number of cattle and sheep kept on the farm and on local temperatures. Parameter estimates were derived from the published literature and using data from the outbreak of bluetongue in northern Europe in 2006. The model was validated using data on the spread of BTV in Great Britain during 2007. The sensitivity of model predictions to the shape of the transmission kernel was assessed. CONCLUSIONS/SIGNIFICANCE The model is able to replicate the dynamics of BTV in Great Britain. Although uncertainty remains over the precise shape of the transmission kernel and certain aspects of the vector, the modeling approach we develop constitutes an ideal framework in which to incorporate these aspects as more and better data become available. Moreover, the model provides a tool with which to examine scenarios for the spread and control of BTV in Great Britain.
Collapse
Affiliation(s)
- Camille Szmaragd
- Institute for Animal Health, Pirbright Laboratory, Pirbright, Surrey, United Kingdom.
| | | | | | | | | | | |
Collapse
|
38
|
Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. Vaccine 2009; 28:1397-403. [PMID: 19895921 DOI: 10.1016/j.vaccine.2009.10.107] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2009] [Revised: 10/09/2009] [Accepted: 10/16/2009] [Indexed: 11/24/2022]
Abstract
The spread of bluetongue virus (BTV) is most successfully controlled by vaccination of susceptible ruminant populations. Currently two different types of BTV vaccines are used for this purpose; inactivated, mostly monovalent vaccine formulations and modified live virus vaccines (MLVs). Clinical signs and viraemia in Dorset Poll sheep vaccinated with BTV-4 and BTV-16 MLVs or inoculated with homogenates of midges (C. sonorensis and C. nubeculosus) previously infected with BTV-4 MLV are presented. All sheep vaccinated with the two MLVs mounted an infectious viraemia lasting for a minimum of 9 up to 23 days post vaccination and developed a range of clinical signs associated with BTV infection. Peak viraemia titres recorded in individual sheep ranged from 3.5 to 6.83 log(10)TCID(50)/ml indicating a high potential for infection of vector insects and onward transmission. The implications of these results are discussed with reference to the current outbreaks of BTV occurring in northern Europe and in relation to the future development of vaccines for this virus.
Collapse
|
39
|
Chaignat V, Worwa G, Scherrer N, Hilbe M, Ehrensperger F, Batten C, Cortyen M, Hofmann M, Thuer B. Toggenburg Orbivirus, a new bluetongue virus: Initial detection, first observations in field and experimental infection of goats and sheep. Vet Microbiol 2009; 138:11-9. [DOI: 10.1016/j.vetmic.2009.02.003] [Citation(s) in RCA: 92] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2008] [Revised: 01/28/2009] [Accepted: 02/03/2009] [Indexed: 11/28/2022]
|
40
|
Abstract
Bluetongue virus (BTV) is the etiological agent of bluetongue, a hemorrhagic disease of ruminants (particularly sheep), which causes important economic losses around the world. BTV is transmitted primarily via the bites of infected midges, which inject the virus into the ruminant's skin during blood feeding. The virus initially replicates in the draining lymph node and then disseminates to secondary organs where it induces edema, hemorrhages, and necrosis. In this study, we show that ovine conventional dendritic cells (cDCs) are the primary targets of BTV that contribute to the primary dissemination of BTV from the skin to draining lymph nodes. Lymph cDCs support BTV RNA and protein synthesis, as well as the production of infectious virus belonging to several different BTV serotypes, regardless of their level of attenuation. Afferent lymph cell subsets, other than cDCs, showed only marginal levels of BTV protein expression. BTV infection provoked a massive recruitment of cDCs to the sheep skin and afferent lymph, providing cellular targets for infection. Although BTV productively infects cDCs, no negative impact on their physiology was detected. Indeed, BTV infection and protein expression in cDCs enhanced their survival rate. Several serotypes of BTV stimulated the surface expression of the CD80 and CD86 costimulatory molecules on cDCs as well as the mRNA synthesis of cytokines involved in inflammation and immunity, i.e., interleukin-12 (IL-12), IL-1beta, and IL-6. BTV-infected cDCs stimulated antigen-specific CD4 and CD8 proliferation as well as gamma interferon production. BTV initially targets cDCs while preserving their functional properties, reflecting the optimal adaptation of the virus to its host cells for its first spread.
Collapse
|
41
|
Chiam R, Sharp E, Maan S, Rao S, Mertens P, Blacklaws B, Davis-Poynter N, Wood J, Castillo-Olivares J. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA). PLoS One 2009; 4:e5997. [PMID: 19543394 PMCID: PMC2694985 DOI: 10.1371/journal.pone.0005997] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2008] [Accepted: 05/23/2009] [Indexed: 11/18/2022] Open
Abstract
Background African horse sickness virus (AHSV) causes a non-contagious, infectious disease in equids, with mortality rates that can exceed 90% in susceptible horse populations. AHSV vaccines play a crucial role in the control of the disease; however, there are concerns over the use of polyvalent live attenuated vaccines particularly in areas where AHSV is not endemic. Therefore, it is important to consider alternative approaches for AHSV vaccine development. We have carried out a pilot study to investigate the ability of recombinant modified vaccinia Ankara (MVA) vaccines expressing VP2, VP7 or NS3 genes of AHSV to stimulate immune responses against AHSV antigens in the horse. Methodology/Principal Findings VP2, VP7 and NS3 genes from AHSV-4/Madrid87 were cloned into the vaccinia transfer vector pSC11 and recombinant MVA viruses generated. Antigen expression or transcription of the AHSV genes from cells infected with the recombinant viruses was confirmed. Pairs of ponies were vaccinated with MVAVP2, MVAVP7 or MVANS3 and both MVA vector and AHSV antigen-specific antibody responses were analysed. Vaccination with MVAVP2 induced a strong AHSV neutralising antibody response (VN titre up to a value of 2). MVAVP7 also induced AHSV antigen–specific responses, detected by western blotting. NS3 specific antibody responses were not detected. Conclusions This pilot study demonstrates the immunogenicity of recombinant MVA vectored AHSV vaccines, in particular MVAVP2, and indicates that further work to investigate whether these vaccines would confer protection from lethal AHSV challenge in the horse is justifiable.
Collapse
Affiliation(s)
- Rachael Chiam
- Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, United Kingdom
| | - Emma Sharp
- Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, United Kingdom
| | - Sushila Maan
- Institute for Animal Health, Pirbright Laboratory, Pirbright, Surrey, United Kingdom
| | - Shujing Rao
- Institute for Animal Health, Pirbright Laboratory, Pirbright, Surrey, United Kingdom
| | - Peter Mertens
- Institute for Animal Health, Pirbright Laboratory, Pirbright, Surrey, United Kingdom
| | - Barbara Blacklaws
- Cambridge Infectious Diseases Consortium, Department of Veterinary Medicine, Cambridge, United Kingdom
| | - Nick Davis-Poynter
- Sir Albert Sakzewski Virus Research Centre, University of Queensland, Herston, Queensland, Australia
| | - James Wood
- Cambridge Infectious Diseases Consortium, Department of Veterinary Medicine, Cambridge, United Kingdom
| | | |
Collapse
|
42
|
Gethmann J, Hüttner K, Heyne H, Probst C, Ziller M, Beer M, Hoffmann B, Mettenleiter T, Conraths F. Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 2009; 27:4118-26. [DOI: 10.1016/j.vaccine.2009.04.072] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2008] [Revised: 04/17/2009] [Accepted: 04/25/2009] [Indexed: 12/01/2022]
|
43
|
Eschbaumer M, Hoffmann B, König P, Teifke JP, Gethmann JM, Conraths FJ, Probst C, Mettenleiter TC, Beer M. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep. Vaccine 2009; 27:4169-75. [PMID: 19406189 DOI: 10.1016/j.vaccine.2009.04.056] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2009] [Revised: 04/11/2009] [Accepted: 04/20/2009] [Indexed: 10/20/2022]
Abstract
Bluetongue has become a major animal health issue in the European Union. The member states and Switzerland have agreed on a vaccination strategy. Three different inactivated monovalent vaccines against bluetongue virus serotype 8 were selected for the compulsory vaccination program carried out in Germany in 2008. The efficacy of these vaccines was evaluated in a pilot study in sheep immunised under field conditions by clinical, virological and serological examination before and after experimental challenge infection with a BTV-8 field isolate. Antibody levels prior to challenge infection differed between the vaccinated groups, but all seroconverted animals were fully protected against clinical disease and virus replication. Only one vaccinated animal was very weakly positive in the real-time RT-PCR at day 10 after challenge infection, and one seronegative sheep in one of the vaccine groups was not protected.
Collapse
Affiliation(s)
- Michael Eschbaumer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Südufer 10, 17493 Greifswald-Insel Riems, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Bhanuprakash V, Indrani BK, Hosamani M, Balamurugan V, Singh RK. Bluetongue vaccines: the past, present and future. Expert Rev Vaccines 2009; 8:191-204. [PMID: 19196199 DOI: 10.1586/14760584.8.2.191] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Bluetongue (BT) is a noncontagious and arboviral disease of both domestic and wild ruminants. The disease is enzootic in areas where reservoirs (cattle and wild ruminants) and vectors exist for the BT virus (BTV). A total of 24 BTV serotypes have been recognized worldwide. The major control measures include restriction of animal movement, vector control applying insecticides, slaughter of infected animals and vaccination. Prophylactic immunization of sheep against BT is the most practical and effective control measure to combat BT infection. At present, attenuated vaccines are used in the Republic of South Africa, the USA and other countries. However, EU countries were using attenuated vaccines, only recently shifting to inactivated vaccines owing to their safety and efficacy. In India, inactivated vaccines are in experimental stages and are expected to be on the market shortly. Inactivated vaccines generate serotype-specific long-lasting protective immunity after two injections, and may help in controlling epidemics. Differentiating infected from vaccinated animals (DIVA) is theoretically possible with inactivated vaccines but has not yet been developed, whereas the attenuated live vaccines are not candidates for DIVA. Attenuated live vaccines are efficacious but safety issues are of great concern. New-generation vaccines (subunit, virus-like particles, core-like particles and vectored) can be employed for DIVA. Recombinant vaccines, which generate cross-protection against multiple BTV serotypes, have great potential in BT vaccine regimens. Furthermore, new-generation vaccines are safe and efficacious experimentally, but large-scale field trials are warranted. Alternative areas, such as antivirals, siRNA, interferon and nanotechnology, may be of future use in the control of BT. We give an overview of BT vaccines, starting from conventional to recent developments, and their feasibility in controlling BT infection.
Collapse
Affiliation(s)
- V Bhanuprakash
- Division of Virology, Indian Veterinary Research Institute, Campus Mukteswar-263 138, Nainital, Uttarakhand, India.
| | | | | | | | | |
Collapse
|
45
|
Abstract
Bluetongue has been recognized as a viral disease of livestock for more than 100 years. Repeated incursions of Bluetongue into Europe since 1998 have been particularly devastating for highly sensitive European fine-wool sheep breeds, and have resulted in a resurgence of interest in vaccine manufacture. Fortunately, the virus and its serology are well understood and vaccination prevents the disease. However, current vaccines are not without their problems, and many new approaches are being tested to improve the safety and breadth of protection afforded. This review describes the leading technologies for improved bluetongue vaccines and looks ahead to how advances in other viral vaccines might be applied to this disease.
Collapse
Affiliation(s)
- Polly Roy
- Department of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E7HT, UK.
| | | | | |
Collapse
|
46
|
Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle. Vet Microbiol 2009; 133:1-8. [DOI: 10.1016/j.vetmic.2008.05.032] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Revised: 05/20/2008] [Accepted: 05/26/2008] [Indexed: 11/22/2022]
|
47
|
A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res 2008; 137:56-63. [DOI: 10.1016/j.virusres.2008.05.016] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2008] [Revised: 05/30/2008] [Accepted: 05/31/2008] [Indexed: 11/23/2022]
|
48
|
Schwartz-Cornil I, Mertens PP, Contreras V, Hemati B, Pascale F, Bréard E, Mellor PS, MacLachlan NJ, Zientara S. Bluetongue virus: virology, pathogenesis and immunity. Vet Res 2008; 39:46. [DOI: 10.1051/vetres:2008023] [Citation(s) in RCA: 204] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2008] [Accepted: 05/19/2008] [Indexed: 11/15/2022] Open
|
49
|
Gubbins S, Carpenter S, Baylis M, Wood JLN, Mellor PS. Assessing the risk of bluetongue to UK livestock: uncertainty and sensitivity analyses of a temperature-dependent model for the basic reproduction number. J R Soc Interface 2008; 5:363-71. [PMID: 17638649 PMCID: PMC2497440 DOI: 10.1098/rsif.2007.1110] [Citation(s) in RCA: 153] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Since 1998 bluetongue virus (BTV), which causes bluetongue, a non-contagious, insect-borne infectious disease of ruminants, has expanded northwards in Europe in an unprecedented series of incursions, suggesting that there is a risk to the large and valuable British livestock industry. The basic reproduction number, R0, provides a powerful tool with which to assess the level of risk posed by a disease. In this paper, we compute R0 for BTV in a population comprising two host species, cattle and sheep. Estimates for each parameter which influences R0 were obtained from the published literature, using those applicable to the UK situation wherever possible. Moreover, explicit temperature dependence was included for those parameters for which it had been quantified. Uncertainty and sensitivity analyses based on Latin hypercube sampling and partial rank correlation coefficients identified temperature, the probability of transmission from host to vector and the vector to host ratio as being most important in determining the magnitude of R0. The importance of temperature reflects the fact that it influences many processes involved in the transmission of BTV and, in particular, the biting rate, the extrinsic incubation period and the vector mortality rate.
Collapse
Affiliation(s)
- Simon Gubbins
- Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Surrey GU24 0NF, UK.
| | | | | | | | | |
Collapse
|
50
|
|